Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 274, Issue 1-2, Pages 28-37Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2014.06.022
Keywords
Experimental autoimmune encephalomyelitis; Camel iridoid glycoside; Multiple sclerosis; JAK/STAT signaling; Neuroinflammation
Categories
Funding
- National Natural Science Foundation of China [81001656, 81341088, 81273817]
- Beijing Nova Star Program in Science and Technology [Z12111000250000]
- Capital Medical Development Special Program [2011-1001-06]
- Beijing Organization Department of Municipal Party Committee Project for Highly Talented Man [2012D005018000010]
Ask authors/readers for more resources
In the present study, we investigated the therapeutic benefit of camel iridoid glycoside (CIG), the main component extracted from Cornus officinalis, in experimental autoimmune encephalomyelitis (EAE) rats. CIG was intragastrically administered daily after EAE initiation for 20 days and reduced disease severity, incidence, disease onset and ongoing paralysis. Histopathological staining showed that CIG could reduce T cell entry to the central nervous system and microglia activation, increased brain-derived neurotrophic factor (BDNF) expression and mature oligodendrocytes, and decreased oligodendrocyte progenitor cells (OPCs). Also, CIG treatment inhibited brain JAK/STAT1/3 and reduced proinflammatory cytokines. CIG might be a novel potential therapeutic agent for multiple sclerosis (MS). (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
